Photobiomodulation Research: April 1, 2026
Share
Your cells are already responding to light right now. Not metaphorically. Literally. The question is whether you're giving them the right kind.
That's the premise behind photobiomodulation (fotobiomodulasjon) — and before you roll your eyes and put this in the "wellness trend" drawer, hear me out. Because in late March 2026, a single PubMed research alert landed with 20 new peer-reviewed studies on this subject alone. Twenty. In one week. That's not a fringe idea quietly bubbling in alternative health circles anymore. That's a field with serious institutional momentum behind it.
I've been using and selling these devices in Norway since 2018. I've watched the research grow from a handful of interesting papers to a genuine body of evidence that now spans everything from diabetic wound healing to myopia progression in children to post-cancer skin recovery. So let me walk you through what's actually being found, what it means in practical terms, and where the honest caveats are. Because there are always caveats, and anyone telling you otherwise is selling you something harder than I ever will.
First: What Is Actually Happening at the Cellular Level?
This is the part most blogs skip, and I think that's a mistake. Because if you understand the mechanism, you can evaluate the claims yourself instead of just taking someone's word for it.
Your mitochondria — the structures inside cells responsible for producing energy — contain light-sensitive proteins called chromophores. The key one for red and near-infrared light is an enzyme called cytochrome c oxidase, which sits at the end of the electron transport chain. When specific wavelengths hit this enzyme (roughly 630nm to 850nm is the meaningful window), it increases ATP production, which is the cell's primary energy currency. More available energy means faster repair processes, reduced local inflammation, and better cellular signalling.
Dr. Michael Hamblin at Harvard has probably done more to establish this mechanism in peer-reviewed literature than anyone. Scott Zimmerman's optics work helped clarify why near-infrared specifically penetrates tissue deeply enough to reach mitochondria in muscle and even brain tissue. Prof. Glen Jeffery at University College London has published extensively on mitochondrial activation through light in the context of eye health and ageing.
This isn't speculative. The cellular mechanism is well established. What's still being worked out is which specific conditions respond best, at what dose, at what wavelength, and for how long. That's what the current wave of clinical research is doing.
There's also something deeper going on that the mainstream papers don't always capture. Dr. Gerald Pollack's work on structured water (what he calls EZ water — the fourth phase of water) suggests that light hitting biological tissue does something to the water inside cells as well. His research, done at the University of Washington, shows that near-infrared light increases the exclusion zone around water-protein interfaces, essentially charging up the cell's internal environment. Dr. Jack Kruse talks about this at length — the idea that light is not just an energy source but a biological signal that organises cellular water, and by extension, everything that depends on intracellular water structure. That's a whole other conversation, but I'll link to some of the related reading at the end. (I find myself going further down that particular rabbit hole every few months.)
What the Late March 2026 Research Actually Found
Let me go through the most significant studies from that batch, in plain English, and be honest about where the evidence is solid versus where it's still early.
Wound healing after childbirth
A Brazilian research group published a study on photobiomodulation applied to episiotomies and perineal tears — the injuries that occur during vaginal delivery. These are painful, common, and typically managed with painkillers and time. Their findings showed reduced pain and accelerated tissue healing compared to control groups. This matters practically because the alternatives are limited and the recovery period affects new mothers significantly. The study used real patients, not a lab model, which adds weight to it.
Reference: Filho et al., Med Sci (Basel), PMID 41892840.
Venous leg ulcers
This one I find particularly interesting because venous leg ulcers are notoriously treatment-resistant. They affect roughly 1% of the population, skew older, and can persist for years with standard wound care. A systematic review and meta-analysis — which is the strongest tier of evidence, pooling results across multiple studies — found that photobiomodulation meaningfully improved healing rates. Meta-analyses take a long time to accumulate because you need enough individual studies first. The fact that this now exists for venous ulcers tells you something about how far the evidence has come.
Reference: Rasul et al., Wound Repair Regen, PMID 41889013.
Brain stimulation in cerebral palsy
Transcranial photobiomodulation is exactly what it sounds like — shining near-infrared light through the skull toward brain tissue. For children with cerebral palsy, researchers are investigating whether this can reduce spasticity, the muscle stiffness and involuntary contractions that significantly affect quality of life. A new scoping review pulled together the existing evidence. The honest summary: it's preliminary, protocols vary widely between studies, and nobody has yet landed on the definitive dose and timing. But the biological rationale is sound — there's consistent evidence that photobiomodulation reduces neuroinflammation — and the non-invasive nature makes it a meaningful area to watch. For parents of kids with CP, this isn't a treatment you'll walk into a clinic and request next month. But it's real science, not wishful thinking.
Reference: Jimenez et al., Brain Sci, PMID 41892615.
Myopia progression in children
This surprised me when I first read it. Myopia (nearsightedness) rates have been increasing globally for decades, and the problem is particularly acute in East Asia. Beyond blurry vision, severe myopia significantly increases the risk of retinal detachment, glaucoma, and other serious conditions later in life. A new review paper makes a case that specific wavelengths of light reaching the retina may influence the eye's growth patterns in ways that could slow myopia progression. This is early-stage, review-level rather than clinical trial level. But the researchers include prominent names in myopia research, and the mechanism being proposed draws on established photobiology. If you have kids spending a lot of time on screens in low light (and here in Norway in winter, that is absolutely the default situation), this one is worth following.
Reference: Gettinger et al., Cells, PMID 41892317.
Bone regeneration after dental surgery
Two studies looked at PBM applied to bone healing after jaw surgery and dental implant procedures. One specifically compared different laser beam profiles (flat versus Gaussian beam shapes) to see whether the shape of light delivery affected outcomes. The other examined osseointegration — how well an implant fuses to surrounding bone. Both found reasons for optimism, with the clear message that dose and delivery technique matter enormously. This is an area where clinical protocols are actively being refined, and the direction of travel is toward standardisation. Faster, better bone healing after implant surgery would be a genuinely significant clinical application.
References: Hanna et al., J Funct Biomater, PMID 41893182; Pereira et al., Lasers Surg Med, PMID 41889270.
Diabetic wound healing
This study examined a specific cellular signalling pathway (PI3K/AKT/mTOR) in hyperglycaemic wounded tissue. The finding was that a particular dose of 830nm light did not activate this pathway — which sounds like a null result but is actually scientifically useful. It tells researchers that this dose achieves its effects through a different mechanism, which helps map the landscape of how photobiomodulation works in the complex biochemical environment of diabetic tissue. Diabetes impairs wound healing through multiple pathways simultaneously, which is why it's so difficult to treat. Understanding which mechanisms are being targeted by which doses is necessary groundwork for effective clinical protocols.
Reference: Kasowanjete et al., Lasers Med Sci, PMID 41888500.
Skin recovery after cancer treatment
Cancer treatment leaves lasting effects on skin — radiation damage, chemotherapy-related changes, surgical scarring, altered pigmentation. A review in Frontiers in Oncology surveyed rehabilitation options for post-cancer skin recovery, and photobiomodulation appeared as one of the modalities with meaningful evidence. For cancer survivors dealing with ongoing skin effects from treatment, this is a practical area where integrative approaches are gaining traction in mainstream clinical thinking.
Reference: Haykal et al., Front Oncol, PMID 41889411.
The Honest Part About the Evidence
I want to be straight with you here, because I find nothing more irritating than breathless health content that presents every study as a breakthrough.
The evidence quality varies significantly by condition. Venous leg ulcers and dental applications are where the evidence base is genuinely solid. Brain stimulation for CP and myopia control are earlier-stage and should be described as promising, not proven. Some of these studies are cell cultures or animal models, not human trials, and the jump from in vitro to clinical application is always significant.
Dosing matters enormously and is not yet standardised across the field. The reason researchers are publishing papers specifically about beam profiles or energy doses is not scientific pedantry — it's because the wrong dose genuinely can produce no effect, or occasionally an opposite one. This is why the "more irradiance must be better" assumption that drives some consumer device marketing is not supported by the biology.
Consumer red light panels — including the ones I sell — are not the same as medical-grade, precisely calibrated clinical research devices. I'll say that clearly. The overlap in mechanism is real, the wavelength ranges are relevant, and there's good reason to believe that high-quality consumer panels produce meaningful biological effects. But they are not equivalent to research-grade equipment, and anyone who tells you differently is oversimplifying. What I will say is that the devices matter — the cheap, unspecified panels flooding the market do not have the output they claim. I test mine with a spectrometer. I have sent panels back when measured output didn't match stated specifications. That should be standard practice. Often it isn't.
What This Means for Us in Norway
Here in Norway, there's a specific context worth thinking about. We spend a significant portion of the year in light conditions that are profoundly different from what our biology evolved under. During mørketid, we're not just missing visible daylight — we're missing the red and near-infrared components of sunlight that drive mitochondrial function. The research on cytochrome c oxidase activation maps directly onto this: the wavelengths most active in cellular energy production are exactly the wavelengths that are absent or minimal in low-angle winter sunlight.
Prof. Glen Jeffery's group at UCL has done work specifically on red light and mitochondrial function in the context of ageing and light deprivation. The implication for those of us spending Norwegian winters primarily under artificial indoor lighting — which contains essentially no red or near-infrared — is not trivial. I've written about this in more depth in the English blog archive, but the short version is: if the cellular machinery that runs on red and near-infrared light is getting almost none of its input signal for four to five months of the year, the research on photobiomodulation starts looking less like an exotic treatment and more like a practical compensatory strategy.
This is also why I'm particularly interested in the myopia research. Kids in Norway spend a lot of time indoors in winter, on screens, under blue-weighted artificial light. If the progression of myopia is influenced by light wavelength reaching the retina, that's an especially relevant finding for this population.
What Properly Specified Actually Looks Like
I'm going to briefly mention devices here because it's directly relevant to the research discussion. The studies cited above used light at specific, calibrated wavelengths and measured doses. When you're evaluating a consumer device, the question is whether the stated wavelengths are accurate and whether the irradiance (power per unit area) is what's claimed.
The red light panels in our collection are specified with actual nanometre figures. I can tell you the emission peaks, the irradiance at various distances, and the evidence base behind those specific wavelengths. I measure them. That's not marketing — it's the minimum information needed to connect a device to the clinical literature.
For portable applications — targeted joint work, localised treatment, travel — the portable and specialist devices carry the same transparency about specifications.
FAQ
What is photobiomodulation and how does it differ from regular red light?
Fotobiomodulasjon is the clinical term for the therapeutic use of specific light wavelengths — typically red (around 630nm to 680nm) and near-infrared (around 800nm to 850nm) — to trigger biological responses in cells. Regular red light from a lamp or LED strip is not photobiomodulation. The distinction is in wavelength specificity, dose, and irradiance. The mechanism involves absorption by cytochrome c oxidase in mitochondria, increasing ATP production and reducing oxidative stress. Consumer "red light therapy" devices overlap with this mechanism when properly specified; most cheap, unspecified devices do not.
Hva er fotobiomodulasjon?
Fotobiomodulasjon er den kliniske betegnelsen for terapeutisk bruk av spesifikke lysbølgelengder — typisk rode (630nm til 680nm) og nar-infrarod (800nm til 850nm) — for a utlose biologiske responser i celler, saerlig via mitokondriene.
Is there real peer-reviewed evidence for red light therapy?
Yes, and it's growing fast. PubMed (the US National Library of Medicine's research database) indexes thousands of peer-reviewed photobiomodulation studies. The evidence is strongest for wound healing, musculoskeletal pain, and certain dental applications. It is earlier-stage but scientifically credible for neurological applications and myopia control. The research referenced in this post comes from a single week of new publications — March 2026.
How do I know if a red light therapy device is actually working at the right wavelengths?
You don't, without measurement. The honest answer is that you have to buy from a source that tests output and can show you the data. I use a spectrometer to verify devices before selling them, and I have sent units back when measured output didn't match claimed specifications. Any company selling therapeutic light devices and unable to provide actual wavelength emission data for their specific units is asking you to take the marketing on faith. I'd suggest not doing that.
Er rødlysterapi trygt?
Generelt ja, nar det brukes riktig. Rødlys og nar-infrarodt lys i de aktuelle bølgelengdeomradene er ikke-ioniserende stråling og anses som trygt ved normal bruk. Standard forholdsregler gjelder for øynene (unnga direkte blikk mot sterke paneler). Personer med lysfølsomme tilstander eller som bruker fotosensitiviserende legemidler bør rådføre seg med lege først.
What conditions have the strongest evidence for photobiomodulation treatment?
As of 2026, the strongest evidence base exists for chronic wound healing (particularly venous leg ulcers and diabetic wounds), musculoskeletal pain and recovery, oral mucositis (mouth sores from cancer treatment), and certain dental/bone healing applications. Evidence for brain-related applications, myopia control, and skin rejuvenation is accumulating but earlier-stage. The honest characterisation is that the field is progressing rapidly, and the picture in two to three years will likely look substantially more complete.
A Closing Thought
What I keep coming back to when I read batches of research like this is that the question has shifted. It's no longer "does this work?" for at least a handful of conditions. It's now "for which conditions, at what dose, and how do we standardise this for clinical use?" That's a profoundly different conversation from where this field was even five years ago.
For us in Norway, dealing with months of light deprivation every winter (mørketid), with the specific cellular consequences that follow from mitochondria getting almost none of their preferred wavelength input for months at a time — this research feels practical, not abstract.
If you want to understand what the devices we carry are actually doing at a cellular level, or if you have questions about specific conditions and what the research says, get in touch. I'd rather give you an honest picture than an enthusiastic one.
And if you want to see what properly specified panels actually look like, start with the red light panel collection.
Disclaimer: The information in this post is educational and based on peer-reviewed research. It does not constitute medical advice. Red light therapy devices are not intended to diagnose, treat, cure, or prevent any medical condition. Always consult a qualified healthcare provider before beginning any new health protocol, particularly if you have an existing medical condition or are taking medication. Results may vary between individuals.
Journal references cited in this post are indexed on PubMed and available by PMID for independent verification.